Showing results (121-130 of 851) with videos related to
Sort By:
Pageof 86
Mayo Clinic Proceedings|March 5, 2008
Serum uric acid: novel prognostic factor in primary systemic amyloidosisShaji Kumar, Angela Dispenzieri, Martha Q Lacy, et al.Hematology/Oncology Clinics of North America|October 25, 2020
Systemic Amyloidosis Due to Clonal Plasma Cell DiseasesGiada Bianchi, Shaji KumarOncology (Williston Park, N.Y.)|September 5, 2014
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myelomaAbhishek Singla, Shaji KumarCancer Treatment and Research|October 4, 2016
Management of Transplant-Eligible Patients with Newly Diagnosed Multiple MyelomaJacob Laubach, Shaji KumarExpert Opinion on Drug Safety|September 30, 2022
An update on the safety of ixazomib for the treatment of multiple myelomaUtkarsh Goel, Shaji KumarSeminars in Hematology|June 26, 2012
Bortezomib combination therapy in multiple myelomaPrashant Kapoor, Vijay Ramakrishnan, S Vincent RajkumarAmerican Journal of Hematology|October 17, 2022
Prevention of infections including vaccination strategies in multiple myelomaHeinz Ludwig, Shaji KumarClinical Medicine Insights. Oncology|March 16, 2013
Efficacy of bortezomib as first-line treatment for patients with multiple myelomaUtkarsh Painuly, Shaji KumarOncology and Therapy|February 22, 2021
Post-Transplant Maintenance Treatment Options in Multiple MyelomaDhauna Karam, Shaji KumarLeukemia & Lymphoma|July 26, 2021
Disease heterogeneity, prognostication and the role of targeted therapy in multiple myelomaSaurabh Zanwar, Shaji KumarPageof 86